The Lancet Oncology Oncology

Organ-preserving multimodal therapy for patients with high-risk upper tract urothelial carcinoma in China (DISTINCT-I): a single-arm, phase 2 trial

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →